Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have received an average rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). About AnaptysBio(Get Free Report)AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation.